GlassScriptPhysician profile
Srinivas Pavuluri
NPI 1255360020
$6,942.00
in general payments reported to CMS, 2019-2025
43 companies · $685 in 2025
The $685 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,058 · 2020: $834 · 2021: $1,169 · 2022: $1,310 · 2023: $964 · 2024: $922 · 2025: $685.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,427 · Education: $144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,427.06 |
| Education | $143.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $1,122.00 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Ucb, INC. | $727.32 | 2019-2024 | Briviact, Rystiggo |
| Abbvie INC. | $668.07 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $486.01 | 2019-2025 | |
| Lundbeck LLC | $326.37 | 2019-2025 | Rexulti, Vyepti |
| Janssen Pharmaceuticals, INC | $303.30 | 2020-2022 | |
| Acadia Pharmaceuticals INC | $292.13 | 2021-2025 | Nuplazid |
| Teva Pharmaceuticals USA, INC. | $266.83 | 2019-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Pfizer INC. | $249.25 | 2023-2025 | |
| Mdd US Operations, LLC | $210.61 | 2023-2025 | Apokyn, Apokyn, Xadago |
| Kyowa Kirin, INC. | $183.29 | 2019-2024 | Nourianz |
| Astrazeneca Pharmaceuticals LP | $167.07 | 2025 | Airsupra, Wainua |
| Sk Life Science, INC. | $159.43 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $140.32 | 2019-2023 | Lyvispah, Rytary |
| Upsher-Smith Laboratories LLC | $139.74 | 2019-2022 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Pavuluri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.